Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial (vol 21, 156, 2021)

被引:19
|
作者
Zhang, Xiaoqiang [1 ]
Li, Shuang [1 ]
Liu, Jing [1 ]
机构
[1] Mengcheng Cty 1 Peoples Hosp, Dept Anaesthesiol, Mengcheng 233500, Anhui, Peoples R China
关键词
Anaesthesia; Benzodiazepine; Hysteroscopy; Propofol; Remifentanil; Remimazolam besylate;
D O I
10.1186/s12871-021-01390-x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Remimazolam besylate is a newer benzodiazepine with characteristics of quick onset of effects, short maintenance and recovery times without accumulation in tissues. This trial was conducted to confirm the efficacy and safety of remimazolam besylate versus propofol during hysteroscopy. Methods: Patients undergoing hysteroscopy were randomly assigned to either the remimazolam (Group R) or the propofol group (Group P). Group R was administered an induction dose of 0.2 mg/kg and a maintenance dosage of 1.0 mg/kg/h. In Group P, propofol was started at 1.5–2.0 mg/kg and then maintained at 3.0–6.0 mg/kg/h. After remimazolam besylate or propofol induction, remifentanil was infused using a target-controlled infusion system with a target concentration of 1.5 ng/ml and titrated during the procedure. The incidence rates of injection pain, low oxygen saturation (SpO2) and adverse effects in both groups were compared. Results: Eighty-two patients were included in this study. The incidence of adverse events in Group R (3.7%) was significantly lower than that in Group P (36.6%) (p < 0.001). The incidence of injection pain in Group P (80.5%) was much higher than that in Group R (2.4%) (p < 0.001). The incidence of other adverse events, such as low SpO2, bradycardia, and hypotension in Group R was lower than that in Group P (p < 0.05). Conclusions: Remimazolam besylate proves to be a safer alternative for anesthesia during hysteroscopy. Moreover, adverse events caused by propofol, such as low SpO2 and injection pain, are largely avoided. Trial registration: This study was approved by the Clinical Research Ethics Committee of Mengcheng County No. 1 People’s Hospital (2020MYL20003) and registered at http://www.chictr.org.cn (15/09/2020, ChiCTR-2000038252). The study protocol followed the CONSORT guidelines. The study protocol was performed in the relevant guidelines. © 2021, The Author(s).
引用
收藏
页数:2
相关论文
共 50 条
  • [1] Correction to: Efficacy and safety of remimazolam besylate versus propofol during hysteroscopy: single-centre randomized controlled trial
    Xiaoqiang Zhang
    Shuang Li
    Jing Liu
    BMC Anesthesiology, 21
  • [2] The efficacy and safety of remimazolam besylate, ciprofol, and propofol during hysteroscopy
    Shan, Weifeng
    Gao, Shuying
    Ai, Mengting
    Lan, Haiyan
    Duan, Gongchen
    Dong, Xiaoli
    Xu, Qiaomin
    Wu, Yini
    Wu, Jimin
    FRONTIERS IN PHARMACOLOGY, 2025, 15
  • [3] Comparison of 95% effective dose of remimazolam besylate and propofol for gastroscopy sedation on older patients: A single-centre randomized controlled trial
    Ye, Enci
    Wu, Keyang
    Ye, Hui
    Zhang, Wenyuan
    Chu, Lihua
    Zhang, Kai
    Xie, Guohao
    Jin, Yue
    Fang, Xiangming
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (11) : 3401 - 3410
  • [4] Comparison of 95% ETective Dose of Remimazolam Besylate and Propofol for Gastroscopy Sedation on Older Patients:A Single-Centre Randomized Controlled Trial
    Ye, Enci
    Wu, Keyang
    Ye, Hui
    Zhang, Wenyuan
    Chu, Lihua
    Zhang, Kai
    Xie, Guohao
    Jin, Yue
    Fang, Xiangming
    ANESTHESIA AND ANALGESIA, 2024, 139 (06): : 2799 - 2801
  • [5] Efficacy and safety of remimazolam tosylate in hysteroscopy: A randomized, single-blind, parallel controlled trial
    Zhang, Shuoya
    Wang, Jiagao
    Ran, Ran
    Peng, Yuchuan
    Xiao, Yun
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2022, 47 (01) : 55 - 60
  • [6] Safety and efficacy of remimazolam versus propofol during EUS: a multicenter randomized controlled study
    Choe, Jung Wan
    Chung, Moon Jae
    Park, Se Woo
    Oh, Dongwook
    Han, Sung Yong
    Yang, Min Jae
    Kim, Eui Joo
    Cho, Jae Hee
    Lee, Kyong Joo
    Jang, Sung Ill
    GASTROINTESTINAL ENDOSCOPY, 2024, 100 (02) : 183 - +
  • [7] Remimazolam-remifentanil causes less postoperative nausea and vomiting than remimazolam-alfentanil during hysteroscopy: a single-centre randomized controlled trial
    Xiaoqiang Zhang
    Shuang Li
    Jing Liu
    BMC Anesthesiology, 23
  • [8] Remimazolam-remifentanil causes less postoperative nausea and vomiting than remimazolam-alfentanil during hysteroscopy: a single-centre randomized controlled trial
    Zhang, Xiaoqiang
    Li, Shuang
    Liu, Jing
    BMC ANESTHESIOLOGY, 2023, 23 (01)
  • [9] Comparison of the Safety and Efficacy of Remimazolam Besylate versus Dexmedetomidine for Patients Undergoing Fiberoptic Bronchoscopy: A Prospective, Randomized Controlled Trial
    Xu, Huiying
    Wang, Lizhen
    Zhu, Wenchao
    Ren, Chunguang
    Liu, Guoying
    Liu, Yanchao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2024, 18 : 2317 - 2327
  • [10] Efficacy and safety of remimazolam tosilate versus propofol in patients undergoing day surgery: a prospective randomized controlled trial
    Luo, Wenchen
    Sun, Minli
    Wan, Jie
    Zhang, Zhenyu
    Huang, Jian
    Zhang, Jinlin
    Xiong, Wanxia
    Xia, Lirong
    Xu, Peiyao
    Miao, Changhong
    Zhang, Xuesong
    Liu, Mingyue
    Zhong, Jing
    BMC ANESTHESIOLOGY, 2023, 23 (01)